预约演示
更新于：2025-11-13
Dexpramipexole Dihydrochloride
右旋普拉克索
更新于：2025-11-13
概要
基本信息
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国)、创新许可和获取途径 (英国) |
登录后查看时间轴
结构/序列
分子式C10H21Cl2N3OS |
InChIKeyAPVQOOKHDZVJEX-LSBIWMFESA-N |
CAS号908244-04-2 |
关联
18
项与 右旋普拉克索 相关的临床试验CTIS2024-510810-33-00
An Open-Label Long-Term Phase III Extension Study to Assess the Long-Term Safety and Tolerability of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5) - AR-DEX-22-04
NCT06533553
An Open-label Phase II Study to Assess the Pharmacodynamic (PD) Effects of Dexpramipexole in Participants With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)
NCT06388889
An Open-Label Long-Term Phase III Extension Study to Assess the Long-Term Safety and Tolerability of Dexpramipexole in Participants With Severe Eosinophilic Asthma
100 项与 右旋普拉克索 相关的临床结果
登录后查看更多信息
100 项与 右旋普拉克索 相关的转化医学
登录后查看更多信息
100 项与 右旋普拉克索 相关的专利（医药）
登录后查看更多信息
74
项与 右旋普拉克索 相关的文献（医药）2025-08-01GENE
Research progress on sepsis-associated encephalopathy by inhibiting pyroptosis
Review
作者: Xu, Dahai ; Luo, Yanhua ; Yu, Chenglin
Sepsis is a life-threatening condition characterized by multiple organ dysfunction syndrome resulted from dysregulated host responses to infection. Sepsis-associated encephalopathy (SAE) is one of the most common symptoms of acute-phase sepsis, with nearly 70 % of patients with sepsis ultimately developing SAE. Pyroptosis represents a type of cell death that is initiated by inflammation. This cell death type is associated with various infectious and noninfectious diseases. The gasdermin family proteins are crucial cell death executors and critical components in regulating the canonical pyroptosis pathway in microglia. In this review, we summarize the inhibitory effects of several drugs and genes on the pyroptosis pathway. Our findings suggest that several drugs (puerarin, VX765, HC067047, dexpramipexole, and Danhong injection), erbin gene, and TRIM45 knockdown improve SAE by suppressing the canonical pathway of NLRP3/caspase-1/gasdermin D-mediated pyroptosis. Therefore, they have significant importance in terms of brain protection. Moreover, we review the relevant literature published in recent years and summarize the research status and development prospects in this field to provide a basis for subsequent related research.
2024-09-01CURRENT TOPICS IN MEDICINAL CHEMISTRY
Recent Advances in the Synthesis of Antioxidant Derivatives: Pharmacological Insights for Neurological Disorders
Review
作者: Kumar, Shivendra ; Mathew, Sojomon ; Singh, Kuldeep ; Shamim ; Gupta, Jeetendra Kumar ; Bhatt, Alok ; Sethi, Pranshul ; Saha, Sunam ; Sharma, Mukesh Chandra
::
Neurological disorders, characterized by oxidative stress (OS) and inflammation, have
become a major global health concern. Redox reactions play a vital role in regulating the balance
of the neuronal microenvironment. Specifically, the imbalance leads to a significant weakening of
the organism's natural defensive mechanisms. This, in turn, causes the development of harmful
oxidative stress, which plays a crucial role in the onset and progression of neurodegenerative diseases.
The quest for effective therapeutic agents has led to significant advancements in the synthesis
of antioxidant derivatives. This review provides a comprehensive overview of the recent
developments in the use of novel antioxidant compounds with potential pharmacological applications
in the management of neurological disorders. The discussed compounds encompass a diverse
range of chemical structures, including polyphenols, vitamins, flavonoids, and hybrid molecules,
highlighting their varied mechanisms of action. This review also focuses on the mechanism
of oxidative stress in developing neurodegenerative disease. The neuroprotective effects of these
antioxidant derivatives are explored in the context of specific neurological disorders, including
Alzheimer's disease, Parkinson's disease, and Huntington's disease. The ultimate goal is to provide
effective treatments for these debilitating conditions and improve the quality of life for patients.
2024-02-01Current opinion in allergy and clinical immunology
Chronic rhinosinusitis with nasal polyps: eosinophils versus B lymphocytes in disease pathogenesis
Review
作者: James, Louisa K. ; Kariyawasam, Harsha H.
Purpose of review:
To highlight the current evidence that supports the view that eosinophils may not drive disease in chronic rhinosinusitis with nasal polyps (CRSwNP) and the emerging evidence for B cells as an important player in this disease.
Recent findings:
Eosinophil depletion studies in CRSwNP do not fully support a critical role for eosinophils in CRSwNP. Almost complete eosinophil depletion with dexpramipexole had no impact on polyp size reduction or clinical improvement. Anti-interleukin (IL)-5 and IL-5Rα inhibition were more effective though with less clinical impact when compared to anti-immunoglobulin E (IgE) or IL-4Rα inhibition strategies. As IL-5Rα is also expressed on CRSwNP derived IgE+ and IgG4+ plasma cells to the same extent as eosinophils, improvements in CRSwNP with IL-5 inhibition may suggest a role for B cells over eosinophils in CRSwNP. We review both eosinophils and B cells in the context of CRSwNP and highlight the current evidence that supports an emerging role for B cells.
Summary:
Despite many aspects of immunopathology in CRSwNP explainable by B cell dysfunction, B cells have so far been ignored in CRSwNP. Further work is needed, as targeting B cells may offer an exciting new therapeutic option in the future.
40
项与 右旋普拉克索 相关的新闻（医药）2025-11-04
·助医服务
临床结果临床2期临床成功临床3期
2025-11-04
·百度百家
临床3期临床2期临床结果细胞疗法基因疗法
2025-11-02
临床3期临床2期申请上市寡核苷酸
100 项与 右旋普拉克索 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 嗜酸性粒细胞性哮喘 | 临床3期 | 美国 | 2023-01-30 | |
| 嗜酸性粒细胞性哮喘 | 临床3期 | 美国 | 2023-01-30 | |
| 嗜酸性粒细胞性哮喘 | 临床3期 | 中国 | 2023-01-30 | |
| 嗜酸性粒细胞性哮喘 | 临床3期 | 日本 | 2023-01-30 | |
| 嗜酸性粒细胞性哮喘 | 临床3期 | 日本 | 2023-01-30 | |
| 嗜酸性粒细胞性哮喘 | 临床3期 | 阿根廷 | 2023-01-30 | |
| 嗜酸性粒细胞性哮喘 | 临床3期 | 阿根廷 | 2023-01-30 | |
| 嗜酸性粒细胞性哮喘 | 临床3期 | 奥地利 | 2023-01-30 | |
| 嗜酸性粒细胞性哮喘 | 临床3期 | 巴西 | 2023-01-30 | |
| 嗜酸性粒细胞性哮喘 | 临床3期 | 巴西 | 2023-01-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 103 | - | 积极 | 2023-08-03 | |||
临床3期 | 616 | (Dexpramipexole 150 mg BID) | 窪鑰網鑰簾齋夢鏇蓋鑰 = 鑰蓋鹽廠繭壓襯醖範築 網範壓築廠壓網憲鏇鬱 (顧鑰廠鑰壓鏇淵齋夢夢, 範鏇構蓋製鬱網艱廠憲 ~ 築獵選願製範膚夢餘廠) 更多 | - | 2022-04-07 | ||
(Dexpramipexole 300 mg/Day) | 構糧鏇願壓鏇衊獵願鬱(積鏇鬱觸鏇糧鏇觸積選) = 積構築淵艱網觸積獵觸 膚衊選簾艱廠遞鑰鹹窪 (窪積餘獵憲淵遞範範餘, 築廠糧繭選憲遞鏇淵網 ~ 遞構製鹹網糧遞鏇襯蓋) 更多 | ||||||
临床2期 | 20 | 鹹衊構構觸鏇顧夢選醖 = 遞範鏇餘窪積齋蓋夢鬱 觸觸醖繭鬱鹹範簾襯鹹 (觸鏇簾築壓積獵築壓窪, 鹽構鏇醖鏇憲淵鬱蓋夢 ~ 鬱簾廠願顧齋鬱壓鬱繭) 更多 | - | 2021-10-12 | |||
临床2期 | 74 | 鬱餘夢夢積構淵鹽餘遞 = 鹹製製選遞餘醖積糧餘 廠襯廠糧願鏇糧遞淵獵 (壓簾廠築蓋選獵鬱簾顧, 醖鹽艱遞壓鏇餘積淵選 ~ 觸廠醖積選範壓顧製淵) 更多 | - | 2021-08-16 | |||
临床3期 | 942 | Placebo (Placebo) | 襯夢窪鬱糧積夢廠膚選(壓襯顧獵選憲選憲艱繭) = 製窪製衊鹽憲鹹襯積蓋 鑰夢繭鏇夢繭選範遞醖 (鬱憲觸簾醖廠獵繭醖構, 鹹鹹窪淵艱遞願壓鹹構 ~ 選繭鏇廠遞衊鹹衊鹹鹽) 更多 | - | 2021-06-07 | ||
(Dexpramipexole) | 襯夢窪鬱糧積夢廠膚選(壓襯顧獵選憲選憲艱繭) = 選糧簾鹽鏇範餘艱願壓 鑰夢繭鏇夢繭選範遞醖 (鬱憲觸簾醖廠獵繭醖構, 鹽餘淵襯範顧遞衊網鹹 ~ 壓鏇膚膚餘糧範製糧夢) 更多 | ||||||
临床2期 | 20 | 蓋遞憲築廠膚網壓衊願(鏇鹽淵廠繭醖築齋製餘) = 鑰衊鏇膚鹽膚齋鏇鑰選 鹹艱蓋築選築壓艱製簾 (築鑰壓願鹽淵鑰蓋顧鬱, 願糧範網膚願艱醖襯衊 ~ 構積觸艱鑰壓顧醖淵範) 更多 | - | 2021-05-18 | |||
临床2期 | 10 | 製選網鏇廠齋構憲廠齋(遞夢襯鹹醖鏇範鏇製淵) = 齋艱醖觸製網鏇憲觸選 願膚構夢鬱蓋襯獵網齋 (餘廠鹽壓製製蓋繭廠構, 6 ~ 98) 更多 | - | 2018-08-02 | |||
临床2期 | 469 | 廠鑰廠選遞簾網遞鏇艱(齋廠廠衊鹹淵夢鬱餘積) = 膚憲顧範鏇衊範艱艱範 鬱繭壓糧膚鹹構鑰鏇網 (窪積鏇鏇範選鬱積簾顧, -0.098 ~ -0.082) | 积极 | 2016-04-05 | |||
临床3期 | 943 | Dexpramipexole 150 mg | 鏇鹹醖齋觸淵鑰簾構簾(獵積窪淵鹽鹹餘獵簾鬱) = 選簾膚壓網糧襯網築築 鑰鹹鹹簾衊製鏇憲鏇顧 (製範築衊遞鹹壓選繭襯 ) | 不佳 | 2013-11-01 | ||
Placebo | 鏇鹹醖齋觸淵鑰簾構簾(獵積窪淵鹽鹹餘獵簾鬱) = 獵築憲蓋願蓋遞憲繭鑰 鑰鹹鹹簾衊製鏇憲鏇顧 (製範築衊遞鹹壓選繭襯 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用